UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of July 2014

001-36203
(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On July 7, 2014, Can-Fite BioPharma Ltd. (the "Company") made available an updated investor presentation on its website. A copy of the investor presentation is attached hereto as Exhibit 99.1 and may be viewed in the Investor Information section of the Company's website at www.canfite.com.

In addition, the 2014 Annual Meeting of Shareholders (the "Annual Meeting") was convened on Monday, July 7, 2014, however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Annual Meeting will be reconvened on Monday, July 14, 2014 at 10:00am, Israel time at the Company's offices located at 10 Bareket Street, Petach Tikva, Israel.

Exhibit Index

Exhibit No.	Description
99.1	Company Presentation, dated July 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Can-Fite BioPharma Ltd.

Date July 8, 2014

By: /s/ Motti Farbstein
Motti Farbstein
Chief Operating and Financial Officer

Exhibit 99.1



CAN-FITE BioPharma Ltd.

Can-Fite Presentation – July 2014

Small Molecules For Big Clinical Needs™

(NYSE MKT:CANF) (TASE:CFBI)

Forward Looking Statement

This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the "SEC"), press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the Tel-Aviv Stock Exchange.

From Concept to Technology



Platform Technology

- **Therapeutic Target**
  - A_3 adenosine receptor (A_3AR)
  - Highly expressed in inflammatory cells
- **Drug product**
  - Small molecules
  - Orally bioavailable drugs
  - A_3AR ligands
- **Pharmacology profile**
  - Anti-inflammatory and anti-cancer effects
- **Therapeutic index**
  - High safety profile and proven efficacy in Phase II clinical studies
- **A_3AR is a Biological Predictive Marker**
  - Used to predict patient's response to the drug



Targeted therapy, specifically aimed at diseased cells

Company Profile

- **Can-Fite BioPharma**
  Advanced clinical stage drug development company

- **Platform technology**
  Small molecule ligands targeting the A3 adenosine receptor to treat:
  - Autoimmune Inflammatory diseases
  - Cancer
  - Ophthalmic diseases

- **Two regional out-licensing deals**
  - Japan: for inflammation (including rheumatoid arthritis and psoriasis)
  - Korea: for rheumatoid arthritis
  - Sizable up front and milestone payments and royalties (significant portion received already)



Equity Profile

Ticker on NYSE: CANF

Ticker on Israeli TASE: CFBI

Price of ADR: $3.75 (1 ADR = 2 Ordinary Shares)

52 Week Range: $3.30 - $9.46

Shares Out: 17.7M Ordinary Shares

Market Capitalization: ~$33M

Avg. Trading Volume (30 day): 25,437 ADRs

As of July 6, 2014

Market Opportunity*

Psoriasis



Rheumatoid Arthritis



Liver Cancer



Glaucoma



Global Data, GIA, Visiongain

Drug Development Pipeline



Corporate Partnership

Regional out-licensing deals

SEIKAGAKU CORPORATION [Traded on the Tokyo Stock Exchange (Ticker:4548)]

- Exclusive license to develop and commercialize CF101 in Japan
- Up to $20 M in upfront, milestone and annual payments ($7.5M received to date)
- Up to 12% royalties

KWANG DONG PHARMACEUTICAL CO., LTD. [Traded on South Korean Stock Exchange (Ticker: A009290)]

- Exclusive regional license to develop and commercialize CF101 for the treatment of rheumatoid arthritis in Korea
- $1.5 M in upfront and milestone payments ($0.5M received to date)
- 7% royalties. Such payments are subject to development and marketing milestones

Scientific Collaborations

Collaborations with two leading medicinal chemistry laboratories in the field of A_3AR for supply of new molecules

- U.S. National Institutes of Health (NIH)
- Leiden University, the Netherlands

CF101 Drug Profile

Properties

- Highly Selective A_3AR Agonist
- Nucleoside derivative
- Molecular weight - 510.29
- Water insoluble
- Orally bioavailable
- Half life time in blood – 8-9 hours
- Is not metabolized in the body

(secreted unchanged)



Fishman et al. Drug Discovery Today 17:359-366. 2011.

Anti-Inflammatory Effect

Proof of concept in pre-clinical pharmacology studies:

- Rheumatoid Arthritis
- Osteoarthritis
- Inflammatory Bowel Disease
- Uveitis

Mechanism of Action



A_3 Adenosine Receptor (A_3AR)

CF101 – Phase II Rheumatoid Arthritis Study

Study Rationale - Phase IIa Data

- Strong correlation found between A_3AR expression in PBMNCs (a class of circulating white blood cells) at baseline and response of patients to CF101 drug treatment

Phase IIa Data



Phase II - Study Protocol

- Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled
- CF101 Administered Orally as Monotherapy for 12 Weeks
- Patients with Active Rheumatoid Arthritis
- Elevated Baseline Expression Levels of A_3 Adenosine Receptor

Study Scheme



Study Primary End Points

- ACR20 response
- Safety parameters

RA Phase II – Efficacy

70% of patients had an over-expression of the Biomarker (>1.5 units) and were eligible to be enrolled to the study

ACR Response Rates



RA Phase II – Efficacy in Naive Patients

Patients with No Prior Systemic Therapy



(NYSE MKT:CANF) (TASE:CFBI)

CANFITE BioPharma Ltd.

CF101 - Psoriasis

Phase II/III - Study Protocol

- Double-blind, placebo-controlled study to test efficacy of CF101 in 300 patients with moderate-to-severe plaque psoriasis
- 3 arms: 1 mg, 2 mg and of CF101 and placebo
  - All patients receiving placebo were switched to either

    1 mg or 2 mg CF101 after 12 weeks
- Study duration 24 weeks
- Interim analysis after 1oo patients

Primary End Point

- PASI 75 and PGA after 12 weeks
- Safety parameters





Psoriasis - Interim Analysis Data

PGA



PASI 75



CF102 for the Treatment of Liver Cancer

Properties

- Highly Selective A3AR Agonist
- Nucleoside derivative
- Molecular weight - 544.73
- Water insoluble
- Orally bioavailable
- Half life time in blood – 12 hours



Anti-Cancer Effect

Proof of concept in pre-clinical pharmacology studies:

- Hepatocellular Carcinoma
- Colon Carcinoma
- Prostate Cancer
- Melanoma

Mechanism of Action



CF102 for the Treatment of Liver Cancer

Phase I/II Proof of Concept Study

Study Synopsis

Phase I/II, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered CF102 in patients with advanced primary liver cancer

Results

- Very favorable safety profile and lack of hepatotoxicity
- Prolongation of survival time
- Regression of skin tumor metastases
- Stable disease (22%)
- Proof of concept for A3AR utilization as a biomarker
- U.S. FDA Orphan Drug Approval (Feb 2012)

Stemmer et al. The Oncologist, 2012

Current Status

Initiation of Phase II study - Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects with Child-Pugh B 78 patients; US, Europe and Israel

Intellectual Property Portfolio

- ✓ Exclusive licensee of the U.S. National Institutes of Health (NIH) and Leiden University in the Netherlands for patents covering A_3AR Agonists
- ✓ 15 patent families
- ✓ 150 patents issued and pending patents applications internationally
- ✓ IP covers composition of matter, synthesis of matter, and clinical applications

Spotlight on 2014 Milestones

Indication	Milestone	Status
Liver Cancer	**Patients' enrollment to Phase II** 78 patients study	Initiation: Q3-2014
Rheumatoid Arthritis	**Phase III planning**	Q4-2014
Psoriasis	**Data from Phase II/III** 300 patients study	Q1-2015
Biomarker	**Development of a commercial kit**	2014



CAN-FITE BioPharma Ltd.

Can-Fite Presentation – July 2014